The objective of this study is to collect the safety and efficacy data of Eraxis IV (anidulafungin) 100 mg according to Korea Ministry of Food and Drug Safety regulations.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
Timeframe: From the time of first dosing of Eraxis until 28 calendar days after last dose of Eraxis
Number of Participants With Discontinuations From Study Treatment Due to Adverse Events (AEs)
Timeframe: From the time of first dosing of Eraxis until 28 calendar days after last dose of Eraxis
Duration of Adverse Events (AEs)
Timeframe: From the time of first dosing of Eraxis until 28 calendar days after last dose of Eraxis
Number of Adverse Events (AEs) by Severity
Timeframe: From the time of first dosing of Eraxis until 28 calendar days after last dose of Eraxis
Number of Participants With Outcome in Response to Adverse Events (AEs)
Timeframe: From the time of first dosing of Eraxis until 28 calendar days after last dose of Eraxis
Percentage of Treatment-Emergent Treatment-Related Adverse Events (AEs)
Timeframe: From the time of first dosing of Eraxis until 28 calendar days after last dose of Eraxis
Number of Participants With Laboratory Abnormalities
Timeframe: From the time of first dosing of Eraxis until 28 calendar days after last dose of Eraxis
Number of Participants With Clinical Response (CR)
Timeframe: From the time of first dosing of Eraxis until 28 calendar days after last dose of Eraxis
Number of Participants With Mycological Response (MR)
Timeframe: From the time of first dosing of Eraxis until 28 calendar days after last dose of Eraxis
Number of Participants With Overall Response (OR)
Timeframe: From the time of first dosing of Eraxis until 28 calendar days after last dose of Eraxis